IDEAS home Printed from https://ideas.repec.org/d/igbfhch.html

Publications

by members of

Berner Fachhochschule → Department Gesundheit → Institut für Gesundheitsökonomie und Gesundheitspolitik

Bern University for Applied Sciences → School of Health Professions → LInstitute of Health Economics and Health Policy

These are publications listed in RePEc written by members of the above institution who are registered with the RePEc Author Service. Thus this compiles the works all those currently affiliated with this institution, not those affilated at the time of publication. List of registered members. Register yourself. Citation analysis. This page is updated in the first days of each month.
| Working papers | Journal articles |

Working papers

2022

  1. Katharina E. Blankart & Frank R. Lichtenberg, 2022, "The Effects of Off-label Drug Use on Disability and Medical Expenditure," NBER Working Papers, National Bureau of Economic Research, Inc, number 30440, Sep.

2021

  1. Avdic, Daniel & Blankart, Katharina, 2021, "A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany," CINCH Working Paper Series (since 2020), Duisburg-Essen University Library, DuEPublico, number 74978, Nov, DOI: 10.17185/duepublico/74978.

Journal articles

2024

  1. Gillner, Sandra & Blankart, Katharina Elisabeth & Bourgeois, Florence Tanya & Stern, Ariel Dora & Blankart, Carl Rudolf, 2024, "The challenges of regulatory pluralism," Health Policy, Elsevier, volume 149, issue C, DOI: 10.1016/j.healthpol.2024.105164.
  2. Katharina E Blankart & Sotiris Vandoros, 2024, "Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation," PLOS ONE, Public Library of Science, volume 19, issue 5, pages 1-23, May, DOI: 10.1371/journal.pone.0301716.
  3. Eva Goetjes & Katharina E. Blankart, 2024, "Insurance barriers and inequalities in health care access: evidence from dual practice," Health Economics Review, Springer, volume 14, issue 1, pages 1-16, December, DOI: 10.1186/s13561-024-00500-y.

2023

  1. Melina Sophie Kurte & Katharina Elisabeth Blankart, 2023, "Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017," International Journal of Health Planning and Management, Wiley Blackwell, volume 38, issue 6, pages 1657-1675, November, DOI: 10.1002/hpm.3692.
  2. Tim Brand & Eva Goetjes & Katharina Blankart, 2023, "To Seek Program Accreditation, Innovation, or Both?—Examining the Interdependencies in High-Reliability Health Care Organizations," Schmalenbach Journal of Business Research, Springer, volume 75, issue 3, pages 281-302, September, DOI: 10.1007/s41471-023-00168-w.

2022

  1. Katharina Blankart & Stefan Felder, 2022, "Arzneimittel: Placebo bei Engpassbekämpfung
    [Pharmaceuticals: Placebo in combating bottlenecks]    ," Wirtschaftsdienst, Springer;ZBW - Leibniz Information Centre for Economics, volume 102, issue 4, pages 248-248, April, DOI: 10.1007/s10273-022-3148-x.

2021

  1. Rucha Vadia & Katharina Blankart, 2021, "Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe," REGION, European Regional Science Association, volume 8, pages 57-81.

2020

  1. Katharina E. Blankart & Friederike Arndt, 2020, "Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany," IJERPH, MDPI, volume 17, issue 11, pages 1-14, June.
  2. Katharina E. Blankart & Frank R. Lichtenberg, 2020, "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, volume 23, issue 4, pages 605-618, December, DOI: 10.1007/s10729-020-09513-5.
  3. Katharina Elisabeth Blankart & Tom Stargardt, 2020, "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., volume 29, issue S1, pages 63-82, October, DOI: 10.1002/hec.4108.

2019

  1. Winter, Vera & Thomsen, Mette Kjærgaard & Schreyögg, Jonas & Blankart, Katharina & Duminy, Lize & Schoenenberger, Lukas & Ansah, John P. & Matchar, David & Blankart, Carl Rudolf & Oppel, Eva & Jensen,, 2019, "Improving Service Provision - The Health Care Services' Perspective," SMR - Journal of Service Management Research, Nomos Verlagsgesellschaft mbH & Co. KG, volume 3, issue 4, pages 163-183, DOI: 10.15358/2511-8676-2019-4-163.

2018

  1. Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt, 2018, "The impact of physician-level drug budgets on prescribing behavior," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 19, issue 2, pages 213-222, March, DOI: 10.1007/s10198-017-0875-9.

2016

  1. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016, "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, volume 120, issue 10, pages 1115-1122, DOI: 10.1016/j.healthpol.2016.08.001.
  2. Hostenkamp, Gisela & Fischer, Katharina Elisabeth & Borch-Johnsen, Knut, 2016, "Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark," Health Policy, Elsevier, volume 120, issue 12, pages 1404-1411, DOI: 10.1016/j.healthpol.2016.09.020.
  3. Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E., 2016, "Dispensing behaviour of pharmacies in prescription drug markets," Health Policy, Elsevier, volume 120, issue 2, pages 190-197, DOI: 10.1016/j.healthpol.2016.01.010.
  4. Katharina Elisabeth Fischer & Tom Stargardt, 2016, "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 17, issue 8, pages 1027-1040, November, DOI: 10.1007/s10198-015-0744-3.

2014

  1. Katharina Elisabeth Fischer & Wolf Henning Rogowski, 2014, "Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe," IJERPH, MDPI, volume 11, issue 5, pages 1-28, May.
  2. Katharina E. Fischer & Tom Stargardt, 2014, "Early Benefit Assessment of Pharmaceuticals in Germany," Medical Decision Making, , volume 34, issue 8, pages 1030-1047, November, DOI: 10.1177/0272989X14546377.
  3. Katharina Fischer & Reiner Leidl, 2014, "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 15, issue 9, pages 899-906, December, DOI: 10.1007/s10198-014-0566-8.

2013

  1. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013, "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, volume 112, issue 3, pages 187-196, DOI: 10.1016/j.healthpol.2013.04.011.
  2. Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski, 2013, "Link between Process and Appraisal in Coverage Decisions," Medical Decision Making, , volume 33, issue 8, pages 1009-1025, November, DOI: 10.1177/0272989X13490837.

2012

  1. Fischer, Katharina Elisabeth, 2012, "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, volume 107, issue 2, pages 218-230, DOI: 10.1016/j.healthpol.2012.07.005.

2011

  1. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011, "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, volume 101, issue 3, pages 290-299, August.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.